Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.

With the introduction of the complement C5-inhibitor eculizumab, a new era was entered for patients with atypical hemolytic uremic syndrome (aHUS). Eculizumab therapy very effectively reversed thrombotic microangiopathy and reduced mortality and morbidity. Initial guidelines suggested lifelong treat...

Descripción completa

Detalles Bibliográficos

Publicado en:	Pediatric Nephrology Vol. 34; no. 11; pp. 2261 - 2278
Autores principales:	Wijnsma, Kioa L., Duineveld, Caroline, Wetzels, Jack F. M., van de Kar, Nicole C. A. J.
Formato:	protocol questions and answers review tables/charts Journal Article
Publicado:	Springer Nature Nov2019
Acceso en línea:	Ver este registro en EBSCOhost